| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Rigel Pharmaceuticals, Inc. |
| 240 East Grand Avenue, South San Francisco, CA 94080 * (650) 624-1100 |
| Business Description | The company is a post-genomic biology company which has developed a new and faster way to find novel drug targets and to validate the role of those targets in diseases without first knowing the identity or sequence of the genes involved. |
|
Filing Information IPO has been | |||
| To Trade As | RIGL (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 2/4/00 |
| Domestic Shares Filed | 9,000,000 | Filing Range | $8.00 - $10.00 |
| Foreign Shares Filed | 0 | Offering Amount | $81,000,000 |
| Company Shares | 9,000,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Warburg Dillon Read LLC | Lead Manager | (203) 719-3000 |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| Robertson, Stephens & Company | Co-manager | (415) 989-8500 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 9/30/98 | 9/30/99 | |||
| Revenues | - | - | - | - | 0.028 | - | 5.898 |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | - | - | - | -5.649 | -10.604 | -6.808 | -7.929 |
| E.P.S | - | - | - | -2.250 | -4.010 | -2.590 | -2.870 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.07 | -5.98 | -7.22 | ||||
| Cash Flow - Inv. | -2.39 | -1.66 | -6.26 | ||||
| Cash Flow - Fin. | 7.81 | 0.64 | 11.17 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/99 | Financial Ratios | ||||
| Total Assets | 17.16 | Current Assets | 8.70 | Current Ratio | 1.17 |
| Total Liab. | 13.11 | Current Liab. | 7.43 | Debt Ratio | 76.37% |
| Total Equity | 4.06 | Working Cap. | 1.27 | Debt to Equity Ratio | 3.23 |
| Cash | 7.19 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development activities, for financing possible acquisitions and investments in technology, for possibly expanding our facilities as well as for working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Brobeck, Phleger & Harrison |
| Registrar/Transfer Agent | Norwest Bank of Minnesota |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Entities affiliated with Lombard Odier & Cie | 26.20 | |
| Entities affiliated with Alta Partners | 16.90 | |
| Entities affiliated with Frazier and Company, Inc. | 15.70 | |
| Novartis Pharma AG | 7.20 | |
| Johnson & Johnson Development Corporation | 6.00 | |
| Note: represents ownership of 5% or more prior to the offering. | ||